Breast cancer: an up‐to‐date review and future perspectives
R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …
associated with many risk factors, including genetic and hereditary predisposition. Breast …
[HTML][HTML] Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
AJ Kerr, D Dodwell, P McGale, F Holt, F Duane… - Cancer treatment …, 2022 - Elsevier
Background Adjuvant and neoadjuvant breast cancer treatments can reduce breast cancer
mortality but may increase mortality from other causes. Information regarding treatment …
mortality but may increase mortality from other causes. Information regarding treatment …
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase …
C Saura, M Oliveira, YH Feng, MS Dai… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE NALA (ClinicalTrials. gov identifier: NCT01808573) is a randomized, active-
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase …
Breast cancer treatments: updates and new challenges
A Burguin, C Diorio, F Durocher - Journal of personalized medicine, 2021 - mdpi.com
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
Tumor angiogenesis: causes, consequences, challenges and opportunities
R Lugano, M Ramachandran, A Dimberg - Cellular and Molecular Life …, 2020 - Springer
Tumor vascularization occurs through several distinct biological processes, which not only
vary between tumor type and anatomic location, but also occur simultaneously within the …
vary between tumor type and anatomic location, but also occur simultaneously within the …
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F Cardoso, S Kyriakides, S Ohno… - Annals of …, 2019 - annalsofoncology.org
In 2018, the predicted number of new breast cancers in 28 European Union (EU) countries
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
was 404 920, with estimated age-adjusted annual incidence of breast cancer of 144.9/100 …
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
R Bradley, J Braybrooke, R Gray, R Hills, Z Liu… - The Lancet …, 2021 - thelancet.com
Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer …
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer …
[HTML][HTML] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast …
HJ Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant… - Annals of …, 2019 - Elsevier
Abstract Background The 16th St. Gallen International Breast Cancer Conference 2019 in
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …
Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies …